DRUGS MADE IN AMERICA ACQUISITION II CORP
Public company snapshot, recent ticker-linked headlines, and a path into evidence-backed AI research.
Latest price
$10.20
+0.00%
Alpha Vantage · 10/30/2026
One-year price history
Adjusted daily closes · 252 observations · as of Oct 30, 2026
1 month
+0.1%
3 months
+0.9%
6 months
+1.8%
1 year
+1.8%
Year to date
+3.0%
52-week range
$9.87 – $10.20
Fundamental snapshot
Latest reported period: Jun 30, 2026
Market cap
$649.7M
P/E
49.9
P/B
-36.2
P/S
—
Revenue
$0
Net income
$13.02M
Diluted EPS
0.3
Gross margin
—
Net margin
—
Return on equity
-73.60%
Total debt
$450K
Cash
$174.97K
Free cash flow
-$1.28M
Latest eight reported quarters
Reported quarterly values, newest first
| Period | Revenue | Net income | Gross margin | Net margin | Free cash flow |
|---|---|---|---|---|---|
| Jun 30, 2026 | $0 | $4.4M | — | — | -$172.75K |
| Mar 31, 2026 | $0 | $4.34M | — | — | -$102.5K |
| Dec 31, 2025 | $0 | $4.33M | — | — | -$314.86K |
| Sep 30, 2025 | $0 | -$46.16K | — | — | -$690.73K |
| Jun 30, 2025 | — | — | — | — | — |
Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.
Recent DMII news
All market newsNo ticker-linked stories are in the current archive.